

# The pharmacokinetics of nifurtimox in chronic renal failure

González-Martin, G.

Thambo, S.

Paulos, C.

Vásquez, I.

Paredes, J.

The pharmacokinetics of nifurtimox, a drug used in the treatment of *Trypanosoma cruzi* infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg·kg<sup>-1</sup> orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher C<sub>max</sub> than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects. © 1992 Springer-Verlag.